Six-month follow up of CTL019 for diffuse large B-cell lymphoma

Bookmark and Share
Published: 10 Dec 2017
Views: 1727
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Dr Schuster speaks with ecancer at the ASH 2017 annual meeting about the six-month analysis of the JULIET trial of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma. 

Read the news story or watch the press conference for more information.